Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.84 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to $0.84; the TTM value through Dec 2025 reached $0.27, changed N/A, while the annual FY2025 figure was $0.39, 108.9% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.84 in Q4 2025 for Soleno Therapeutics, up from $0.47 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.84 in Q4 2025 and bottomed at -$0.95 in Q1 2025.